From first-generation hepatitis C virus protease inhibitors to direct-acting antivirals: Self-reported symptoms as a warning signal for potential adverse events (ANRS HC26, ANRS HC27 trials)

European Journal of Gastroenterology and Hepatology

Volumn 28, Issue 6, 2016, Pages 732-734

  Marcellin, Fabienne ^a,b,c   Fournier, Isabelle ^d   Carrieri, Maria P ^a,b,c   Poizot Martin, Isabelle ^a,b   Cotte, Laurent ^e  

^a AIX MARSEILLE UNIV   (France)

^b AIX MARSEILLE UNIVERSITY   (France)

^c OBSERVATOIRE RÉGIONAL DE LA SANTÉ PROVENCE ALPES CÔTE D AZUR   (France)

^d INSERM   (France)

^e CROIX ROUSSE HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

AMIODARONE; BOCEPREVIR; PEGINTERFERON; PROTEINASE INHIBITOR; RIBAVIRIN; SOFOSBUVIR; TELAPREVIR; ANTIVIRUS AGENT;

DYSPNEA; FLU LIKE SYNDROME; GASTROINTESTINAL SYMPTOM; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; LETTER; NAUSEA; NONHUMAN; PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; SELF REPORT; SKIN DISEASE; SLEEP DISORDER; UNSPECIFIED SIDE EFFECT; DRUG EFFECTS; HEPACIVIRUS;

ANTIVIRAL AGENTS; HEPACIVIRUS; HEPATITIS C; HUMANS; PROTEASE INHIBITORS; RIBAVIRIN; SELF REPORT;

EID: 84966431254     PISSN: 0954691X     EISSN: 14735687     Source Type: Journal    
DOI: 10.1097/MEG.0000000000000612     Document Type: Letter

References (5)

1. Nicolini LA, Menzaghi B, Ricci E, Martinelli C, Magni C, Maggi P, et al. Effectiveness of first-generation HCV protease inhibitors: does HIV coinfection still play a role? Eur J Gastroenterol Hepatol 2016; 28:37-41.
2. Cotte L, Braun J, Lascoux-Combe C, Vincent C, Valantin MA, Sogni P, et al. French National Agency for Research on AIDS and Viral Hepatitis (ANRS) HC26 Study Group. Telaprevir for HIV/hepatitis C viruscoinfected patients failing treatment with pegylated interferon/ribavirin (ANRS HC26 TelapreVIH): an open-label, single-arm, phase 2 trial. Clin Infect Dis 2014; 59:1768-1776.
3. Poizot-Martin I, Bellissant E, Garraffo R, Colson P, Piroth L, Solas C, et al. Addition of boceprevir to PEG-interferon/ribavirin in HIV-HCV genotype 1 coinfected, treatment-experienced patients: efficacy, safety and pharmacokinetics data from the ANRS HC27 study. HIV Clin Trials 2016; [Epub ahead of print].
4. Fried MW, Shiffman ML, Reddy KR, Smith C, Marinos G, Gonçales FL Jr, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002; 347:975-982.
5. Fontaine H, Lazarus A, Pol S, Pecriaux C, Bagate F, Sultanik P, et al. Bradyarrhythmias associated with sofosbuvir treatment. N Engl J Med 2015; 373:1886-1888.